Article metrics

Original research
Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer

 

Online download statistics by month:

Online download statistics by month: May 2022 to October 2024

AbstractFullPdf
May 202222322593
Jun 2022449452206
Jul 2022299301116
Aug 2022282288106
Sep 202219820664
Oct 202221221283
Nov 202219719748
Dec 202212112143
Jan 2023848429
Feb 202310110351
Mar 2023676846
Apr 2023686935
May 2023717228
Jun 2023676735
Jul 2023646436
Aug 2023575731
Sep 2023626323
Oct 2023474731
Nov 2023676729
Dec 2023505134
Jan 2024414146
Feb 2024626233
Mar 2024585883
Apr 2024474737
May 2024444536
Jun 2024636240
Jul 2024596039
Aug 2024524924
Sep 2024595934
Oct 2024585830
Total332933551569